Twist Bioscience Corporation stocks have been trading up by 8.35 percent after a transformative synthetic biology partnership boosted investor optimism.
Click Here for a Millionaire's POV on Trading TWST
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Twist Bioscience signed an agreement to provide antibody characterization data and services to Eli Lilly’s AI/ML drug discovery platform, TuneLab, feeding high-quality lab data into Lilly’s AI models.
- Shares of TWST rose, including moves of over 4%, after the Lilly TuneLab deal headlines hit, signaling strong trading interest around the AI collaboration theme.
- Leerink raised its price target on Twist Bioscience from $120 to $160 with an Outperform rating, tying upside to a large, early-stage AI drug discovery opportunity.
- Twist Bioscience said its pilot work on AI-designed mini-binder proteins for Anthropic is “probably sort of” already baked into its fiscal 2027 orders outlook.
- A recent Form 4 filing disclosed changes in beneficial ownership of Twist Bioscience securities by an insider or major shareholder.
Live Update At 12:32:41 EDT: On Thursday, September 24, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 8.35%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TWST has been trading like a high-voltage growth name. Over the last few weeks, Twist Bioscience stock ran from a close of $124.72 on 2026/09/04 to $171.735 on 2026/09/24. That’s a powerful uptrend with only brief pauses, the kind of staircase move momentum traders love to stalk.
Intraday on 2026/09/24, TWST opened at $157.72, flushed to $156.83, then powered as high as $179.92 before settling near $171.74. That intraday range shows serious speculative energy and liquidity — ideal conditions for day trading and swing trading, but also a reminder that risk can spike fast.
More Breaking News
- Beneficient Stock Explodes As Debt Dispute Fuels 328% Spike
- UWMC Stock Slides As Hedging Losses And Dilution Rattle Traders
- SKYQ Stock Pulls Back As Traders Watch Key Support
- Everpure Stock Jumps As S&P 500 Inclusion Fuels Buying
Fundamentally, Twist Bioscience is still a classic high-growth, high-burn story. Revenue over the last year was about $376.6M, growing at a double-digit clip, and gross margin sits near 52%, which is strong for a platform biotech. But TWST is not yet profitable: operating margin is roughly -31.8%, and return on equity is deeply negative, around -29%. Cash looks reasonable for now, with a current ratio of 2.7 and limited leverage, but the price-to-sales ratio above 25 says traders are paying up for future AI and synthetic biology optionality, not today’s earnings.
Why Traders Are Watching TWST Right Now
The real spark for TWST this month is the AI drug discovery story. Twist Bioscience locked in an agreement with Eli Lilly to provide antibody characterization data and services to Lilly’s AI/ML TuneLab platform. In plain English, TWST becomes a key wet-lab engine feeding real experimental antibody data into Lilly’s AI models such as AbLab.
For traders, that matters because AI drug discovery is where narrative, tech, and pharma budgets collide. Twist Bioscience isn’t just selling DNA or antibodies; with TuneLab, TWST is wiring its protocols directly into a big pharma AI stack. TuneLab users can order antibody services via preferred Twist protocols and get clean data that trains Lilly’s models and speeds up antibody discovery. That’s a sticky workflow position, not just a one-off contract.
The tape confirmed the impact. Multiple reports flagged TWST shares jumping, including moves over 4%, right after the Lilly TuneLab news hit on 2026/09/16. TWST traded like a momentum breakout, with follow-through in the days after as the story spread across the biotech and AI trading crowd.
Layer on top the fresh analyst call. Leerink raised its TWST price target from $120 to $160 while keeping an Outperform rating, explicitly citing conservative revenue targets and a “large, early-stage AI drug discovery opportunity.” That kind of upgrade doesn’t guarantee anything, but it reinforces that at least one major Wall Street shop sees the Lilly relationship — and broader AI work — as a real revenue driver, not just hype.
TWST also confirmed that its pilot work on AI-designed mini-binder proteins for Anthropic is already “probably sort of” included in its fiscal 2027 orders outlook. For traders, that means the Anthropic collaboration is real, but it’s not some secret upside; it’s part of the base case growth story.
Conclusion
Twist Bioscience is turning into a textbook case of how AI narratives can re-rate a growth stock — and why traders need to stay sharp. On one side, TWST now has a high-profile seat inside Lilly’s TuneLab platform, providing antibody characterization data that powers AI antibody discovery. The market liked it, as seen in TWST’s strong price action and the post-news surge of more than 4% on 2026/09/16.
On the other side, the fundamentals still show heavy losses. TWST posted quarterly revenue of about $118.4M with a gross profit of $62.5M, but net income was a loss of roughly $35.1M. Free cash flow for the quarter was around -$8.6M, even after meaningful stock-based compensation. The valuation is rich, with TWST trading at over 25x sales and more than 24x book value, so the bar for future execution is high.
The Anthropic mini-binder project and the Form 4 insider activity round out the picture. They remind traders that while AI and synthetic biology open big doors, nothing here is risk-free or linear. That’s exactly why disciplined risk management matters so much in this kind of volatile name.
For active traders studying TWST, this is a classic momentum-learning setup: strong news, strong trend, and real-but-costly growth. As Tim Sykes likes to say, “The market rewards preparation, not hope — study the spikes, plan the trades, and always cut losses quickly.” And in the same spirit of trading discipline, As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” This article is for educational and research purposes only, but the TWST chart and news flow offer plenty to study.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.